NEW YORK, Jan. 20, 2011 /PRNewswire-USNewswire/ -- The 5th Drug Discovery for Neurodegeneration, a two-day course to be held February 6-8, 2011 in San Diego, CA, will bring together 30 top researchers committed to accelerating drug discovery for neurodegeneration. The program will focus on five major topics: Basics of Medicinal Chemistry, Early Phases of Drug Discovery, Pre-Clinical Proof-of-Concept and Development, Natural Products, Biologics and Repurposing, Issues in Technology Transfer: Interactions and Intellectual Property, and Resources and Services For Advancing Drug Discovery.
"This year's course is particularly important," said Dr. Howard Fillit, ADDF's Executive Director. "Advances in basic science and experimental research are rapidly bringing drug discovery for neurodegeneration closer to important and practical applications."
This course focuses on the complex processes of translating basic research into novel therapies by providing participants with knowledge and relevant resources about this field of scientific investigation while addressing the associated barriers and challenges. The CME accredited course attracts a multi-disciplinary network of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases or CNS, business development and licensing professionals, alliance management professionals, venture capitalists and other investors.
This event is presented by the ADDF and is also supported by a conference grant: U13-AG031125 from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke. Additional sponsors include Merck Research Laboratories, the Michael J. Fox Foundation for Parkinson's Research, The ALS Therapy Development Institute, Fast Forward, LLC, JSW Life Sciences, and Novus Biologicals. Sponsorship and exhibition opportunities are still available.
FOR DETAILS AND TO REGISTER, VISIT: www.alzdiscovery.org.
Group discounts are available! Please contact the Conference Secretariat at email@example.com.
About the Alzheimer's Drug Discovery Foundation (ADDF)
The ADDF (www.AlzDiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 17 countries.
SOURCE Alzheimer's Drug Discovery Foundation